Ultime notizie per P3 Health Partners (NASDAQ:PIII) Azioni

P3 Health Partners

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

Long Ideas

News

Penny Stocks

Pre-Market Outlook

Markets

Trading Ideas

BCOV

PIII

PODC

Scopri le penny stock sotto i $3 che gli insider stanno acquistando, tra cui PodcastOne e altre opportunità nascoste.

Le migliori penny stock sotto $3 che gli insider stanno acquistando

P3 Health Partners Inc. - Class A Common Stock

P3 Health Partners Inc

Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is sitting on nearly 2,400 unsold Cybertrucks across the U.S., according to new data from <a href="https://tesla-info.com/blog/inventory-stats-regional/US?q=1">Tesla-Info</a>. That's about $200 million worth of inventory for a vehicle CEO <a href="https://www.benzinga.com/news/25/03/44536773/demand-is-off-the-charts-elon-musk-claimed-tesla-had-over-1-million-cybertruck-reservations-just-46096-have-been-sold-in-14-months">Elon Musk once said</a> had &#8220;over 1 million&#8221; reservations. But more than a year after deliveries began, the Cybertruck has become a tough sell.
<h2 class="wp-block-heading">Sluggish Sales, Rising Inventory</h2>
When the Cybertruck was first unveiled in 2019, Musk said it would start at $39,900. But the base model came out at $60,990, and early Foundation Series editions were priced close to $100,000. That sticker shock, combined with frequent quality issues, has eroded trust.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/startengine-own">The $1.3 billion startup investment boom: How this company's explosive growth is opening doors for everyday investors with a new $500 minimum</a></li>
</ul>
The Cybertruck officially launched in late 2023. Since then, Tesla has sold just over 46,000 units, based on recall <a href="https://www.nhtsa.gov/recalls?nhtsaId=25V170000">data</a> released by the National Highway Traffic Safety Administration. That's a far cry from the 250,000 annual units Musk promised, or the millions of eager buyers he once claimed were lined up.
Ross Gerber, CEO of Gerber Kawasaki Wealth and Investment Management, was direct: "Tesla has sold only 47k Cybertrucks total, according to the recall notice. This is <a href="https://www.benzinga.com/markets/equities/25/03/44429500/teslas-cybertruck-sales-at-just-47k-is-really-bad-for-250k-target-says-ross-gerber-amid-recall-troubles">really bad for a product</a> that was supposed to sell 250k units a year."&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tesla has sold only 47k Cybertrucks total according to the recall notice. This is really bad for a product that was supposed to sell 250k units a year. <a href="https://twitter.com/search?q=%24tsla&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$tsla</a>
&mdash; Ross Gerber (@GerberKawasaki) <a href="https://twitter.com/GerberKawasaki/status/1902812229172596943?ref_src=twsrc%5Etfw">March 20, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Trending: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.
What makes this inventory pile-up worse is that Tesla has reportedly paused trade-ins on Cybertrucks, according to <a href="https://electrek.co/2025/04/01/tesla-is-sitting-on-200-million-worth-of-cybertruck-inventory/">Electrek</a>. Several owners said they tried to swap their trucks for another vehicle but were told Tesla isn't accepting its own model as a trade-in.&nbsp;
<h2 class="wp-block-heading">Mounting Recalls and Customer Frustration</h2>
Adding to the pressure, <a href="https://www.benzinga.com/markets/equities/25/03/44414187/elon-musks-tesla-recalls-over-46000-cybertrucks-due-to-safety-concerns">Tesla recently issued a recall</a> for all Cybertrucks because a stainless-steel trim piece, called the cant rail, could detach while driving. It's one of eight recalls in just over a year, with other issues ranging from windshield wipers and delayed rearview cameras to stuck accelerator pedals.
In some cases, Tesla service centers have kept trucks for extended periods. Some <a href="https://in.benzinga.com/personal-finance/25/03/44249300/tesla-cybertruck-owner-says-hes-lost-70k-in-business-over-backlash-customers-hate-it-but-he-loves-it-the-best-truck-ive-ever-had">frustrated owners tried to return</a> their vehicles, but the company directed them to go through Lemon Law claims instead.
See Also: <a href="https://www.benzinga.com/money/how-a-10k-bet-on-health-care-originals-could-have-skyrocketed-your-portfolio">With Shares Starting at Just $1.52, This Could be Your Chance to Invest in the Future of Healthcare.</a>
Meanwhile, Electrek reported that used Cybertruck prices have plunged and are 55% down year over year, 13% in the last three months, and 6% just in the past month.
Tesla appears to be slowing Cybertruck production to keep inventory from ballooning further as it&#8217;s holding a growing fleet of high-priced trucks that more people seem to be walking away from than buying.
Read Next:
<ul>
<li>This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

TSLA

Tesla Has Over $200 Million Worth Of Cybertrucks In Inventory—And That's Raising Questions About Demand (Again)

Morgan Stanley analyst Betsy Graseck maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Equal-Weight and lowers the price target from $29 to $22.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Regions Finl, Lowers Price Target to $22

Morgan Stanley analyst Betsy Graseck maintains State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) with a Overweight and lowers the price target from $132 to $102.

Morgan Stanley Maintains Overweight on State Street, Lowers Price Target to $102

U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 800 points on Monday.
The Dow traded down 2.14% to 37,494.77 while the NASDAQ dipped 1.24% to 15,393.88. The S&amp;P 500 also fell, dropping, 1.59% to 4,993.52.
Check This Out: <a href="https://www.benzinga.com/25/04/44664754/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-delivering-high-dividend-yields-5">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields</a>
Leading and Lagging Sectors Information technology shares surged by 4.7% on Monday.
In trading on Monday, consumer staples shares rose by just by 0.7%.
Top Headline
The Manheim Used Vehicle Value Index fell 0.7% month-over-month in March, matching the pace of decline in the previous month.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Janover Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) shares shot up 332% to $17.27. Janover raised $42 million in convertible notes and warrants from Pantera Capital, Kraken, Arrington Capital, and others.</li>
<li>Shares of Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>)got a boost, surging 16% to $52.31. Newsmax entered into standby equity purchase agreement for up to $1.2 billion with Yorkville Advisors.</li>
<li>Chanson International Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHSN#NASDAQ">CHSN</a>) shares were also up, gaining 70% to $0.3722 as the company reported a year-over-year increase in FY24 financial results.</li>
</ul>
Equities Trading DOWN
<ul>
<li>TAL Education Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) shares dropped 8% to $11.27. Shares of US-listed Chinese companies traded lower after President Trump last week imposed 34% tariffs on China. In retaliation, China imposed a 34% tariff on US goods.</li>
<li>Shares of China Pharma Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#NYSE">CPHI</a>) were down 31% to $0.1532 as the company reported a 1-for-10 reverse stock split.</li>
<li>reAlpha Tech Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>) was down, falling 42% to $0.6062 as the company announced exercise of warrants for $3.1 million gross proceeds.</li>
</ul>
Commodities In commodity news, oil traded down 2.1% to $60.72 while gold traded down 0.6% at $3,017.70.
Silver traded up 3.2% to $30.150 on Monday, while copper fell 3.3% to $4.2565.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 3.99%, Germany's DAX 40 dipped 3.67% and France's CAC 40 fell 4.3%. Spain's IBEX 35 Index fell 4.62%, while London's FTSE 100 dipped 3.87%.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei 225 dipping 7.83%, China's Shanghai Composite falling 7.34%, Hong Kong's Gang Seng index dipping 13.22% and India's BSE Sensex falling 2.95%.
Economics
The Manheim Used Vehicle Value Index fell 0.7% month-over-month in March, matching the pace of decline in the previous month.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44665280/how-to-earn-500-a-month-from-walgreens-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

AIRE

CHSN

CPHI

JNVR

NMAX

Crude Oil Down 2%; Chanson International Shares Spike Higher

WIIM

ReAlpha Tech shares are trading lower. The company announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 4,218,751 shares of common stock.

Morgan Stanley analyst Betsy Graseck maintains Truist Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) with a Equal-Weight and lowers the price target from $50 to $43.

Morgan Stanley Maintains Equal-Weight on Truist Finl, Lowers Price Target to $43

Morgan Stanley analyst Betsy Graseck maintains U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) with a Overweight and lowers the price target from $55 to $51.

Morgan Stanley Maintains Overweight on U.S. Bancorp, Lowers Price Target to $51

Morgan Stanley analyst Betsy Graseck maintains PNC Financial Services Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) with a Underweight and lowers the price target from $188 to $179.

Morgan Stanley Maintains Underweight on PNC Financial Services Gr, Lowers Price Target to $179

Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) on Monday released topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the treatment of <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">acquired hypothalamic obesity</a>.
Acquired hypothalamic obesity is&nbsp;a rare, non-genetic form of obesity resulting from damage to the hypothalamus, the brain region controlling energy balance, often caused by tumors, surgery, or radiation, leading to rapid weight gain <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44663146/rhythm-pharmaceuticals-announces-pivotal-phase-3-transcend-trial-meets-primary-endpoint-with-19-8-" rel="noreferrer noopener">and metabolic complications</a>.
The global trial met its primary endpoint with a statistically significant and clinically meaningful reduction in body mass index (BMI) with setmelanotide in adult and pediatric patients versus placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42627167/rhythm-pharmaceuticals-obesity-treatments-target-less-crowded-space-analyst-sees-long-term-potential" rel="noreferrer noopener">Rhythm Pharmaceuticals&#8217; Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential</a>
Highlights from the topline data include:
<ul>
<li>-19.8% placebo-adjusted difference in BMI reduction (N=120).</li>
<li>The primary endpoint of mean BMI reduction was -16.5% from baseline for all patients on setmelanotide therapy (n=81) compared with +3.3% BMI change for patients on placebo (n=39) at 52 weeks.</li>
<li>80% of patients on setmelanotide achieved a BMI reduction of 5% or greater at 52 weeks.</li>
<li>-19.2% placebo-adjusted BMI reduction was achieved in adult patients (n=49) and -20.2% in patients younger than 18 (n=71) at 52 weeks.</li>
</ul>
The company says the global Phase 3 TRANSCEND trial is believed to be the largest and longest placebo-controlled trial to evaluate therapy for patients with acquired hypothalamic obesity. The double-blinded, 52-week trial enrolled 120 patients.
Clinically meaningful improvements were observed across key secondary endpoints at week 52, including:
<ul>
<li>83% of patients on setmelanotide therapy achieved 5% or greater reduction in BMI (n=33 patients 18 or older) or BMI Z-score reduction of 0.2 or greater points (n=48 patients younger than 18).</li>
<li>-1.4 placebo-adjusted mean change in the weekly average of the daily maximal hunger score for patients 12 years old or older (n=81) (p=0.003).</li>
</ul>
No new safety signals with setmelanotide were observed, in line with setmelanotide&#8217;s well-established and well-understood safety profile. Consistent with prior clinical experience, setmelanotide was generally well tolerated in the TRANSCEND study.
The most common treatment-emergent adverse events (affecting &gt;20% of participants) were nausea, vomiting, diarrhea, injection site reaction, skin hyperpigmentation, and headache. No serious adverse events leading to study discontinuation were reported.
Price Action: RYTM stock is up 15.60% at $54.27 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44651786/lamb-weston-may-keep-cutting-prices-to-win-back-market-share-but-demand-recovery-remains-uncertain-says-analyst" target="_blank" rel="noreferrer noopener">Lamb Weston May Keep Cutting Prices To Win Back Market Share, But Demand Recovery Remains Uncertain</a></li>
</ul>
Photo by earthphotostock via Shutterstock

Biotech

Health Care

General

RYTM

Rhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity Disorder

Morgan Stanley analyst Betsy Graseck maintains Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) with a Overweight and lowers the price target from $98 to $94.

Morgan Stanley Maintains Overweight on Bank of New York Mellon, Lowers Price Target to $94

Morgan Stanley analyst Betsy Graseck maintains Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) with a Overweight and raises the price target from $79 to $80.

Morgan Stanley Maintains Overweight on Wells Fargo, Raises Price Target to $80

A chaotic and volatile session kicked off the new week on Wall Street, with a start that offers <a href="https://www.benzinga.com/markets">little reason for optimism.</a>
The S&amp;P 500 opened with a gap below 4,900 points, then fiercely rebounded in the first hour of trading before the gains swiftly evaporated. Sentiment further deteriorated after Donald Trump adopted a more aggressive tone toward China.
On Truth Social, Trump stated that China had imposed retaliatory tariffs of 34%, on top of what he described as already record-setting tariffs, despite prior warnings that such measures would be met with significantly higher U.S. tariffs. He added that if China did not reverse the 34% hike by April 8, the United States would respond with additional tariffs of 50%, effective the following day.
He also indicated that all discussions with China regarding their requested meetings would be terminated, while negotiations with other countries that had expressed interest in talks would begin immediately.
The European Union signaled openness to implementing a zero-for-zero tariff agreement on industrial goods with the United States.
By 12:40 p.m. ET, the S&amp;P 500 was down 0.8%, the Nasdaq 100 fell 0.2%, and the Dow dropped 1.4%. Every sector remained in the red, with real estate and materials leading the losses.
In commodities, gold slipped 1.2%, heading for its third consecutive session of declines, while oil prices fell 2.3% to $60 a barrel, now down 16% from last week&#8217;s highs.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), which had been spared from last week&#8217;s global market rout, joined the bloodbath over the weekend, dropping 6.4% on Sunday and holding at $78,000 on Monday.
<h2 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>Chg %</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,363.12</td>
<td>-0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,026.51</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,806.00</td>
<td>-1.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>37,781.52</td>
<td>-1.4%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:40 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) eased 0.7% to $502.84.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 1.2% to $378.31.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;eased 0.2% to $421.93.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.9% to 179.64.</li>
<li>The&nbsp;Consumer Staples&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up 0.1%; the&nbsp;Real Estate&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) lagged, down 2.2%.</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Major Gainers</h3>
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) up 9.03% to $32.51</li>
<li>Dollar Tree, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) up 5.61% to $71.34</li>
<li>Hewlett Packard Enterprise (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) up 5.16% to $13.45</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) up 4.74% to $61.89</li>
<li>EQT Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) up 4.65% to $48.26</li>
<li>Arista Networks Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>) up 4.65% to $67.36</li>
<li>Microchip Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) up 4.64% to $37.90</li>
</ul>
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Major Losers</h3>
<ul>
<li>Schlumberger Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) down 5.39% to $32.91</li>
<li>Eversource Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ES#NYSE">ES</a>) down 5.12% to $55.35</li>
<li>Genuine Parts Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) down 5.07% to $110.88</li>
<li>Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) down 5.03% to $56.03</li>
<li>AutoZone, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) down 4.96% to $3,472.18</li>
<li>NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) down 4.80% to $54.50</li>
<li>The Home Depot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) down 4.77% to $337.01</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44667862/oil-crashes-to-60-per-barrel-as-recession-fears-grow">Oil Crashes To $60 Per Barrel As Global Recession Fears Grow</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Government

Large Cap

Macro Economic Events

Regulations

Broad U.S. Equity ETFs

Economics

Tech

ETFs

$BTC

ANET

SPDR Dow Jones Industrial Average ETF Trust

DLTR

LRCX

MCHP

SMCI

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Turmoil Deepens As Trump Threatens Massive China Tariffs, Bitcoin Wobbles At $78K: What's Driving Markets Monday?

Wedbush tech analyst Dan Ives on Monday shared his thoughts on where investors may find safe havens with the tech industry as the market volatility continues under the uncertainty of <a href="https://www.benzinga.com/25/04/44665493/us-recession-countdown-has-begun-as-trump-tariffs-push-odds-to-45-goldman-sachs-warns">Trump's tariff policies.&nbsp;</a>
What To Know: In a note to investors released Monday, Ives gave more insight into his recent comments on the potential effects of the new tariff policies and which tech stocks could outperform the rest of the sector in the volatile market conditions.&nbsp;
Cybersecurity names could outperform other stocks in the tech sector, according to Ives.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/04/44667862/oil-crashes-to-60-per-barrel-as-recession-fears-grow">Oil Crashes To $60 Per Barrel As Global Recession Fears Grow&nbsp;</a>
He listed ZScaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>), Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), CrowdStrikeHoldings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) as "defensive names where investors could rotate from semis to software to hunker down during this Category 5 storm."&nbsp;
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) remain Ives' top names to own and even with "this massive near-term uncertainty it does not change their installed base, technology leadership, and long-term growth opportunities ," the Wedbush analyst said.&nbsp;
Ives reiterated his calls for President Donald Trump to begin negotiations to reduce or eliminate tariffs which have led to the most difficult investing landscape in his "25 years covering tech stocks on the Street."
Earnings estimates will need to be reevaluated by the Street and Ives warned that most companies will likely not offer any forward guidance on their upcoming Q1 conference calls.&nbsp;
"Today will be a scary day for investors (and us) … it will create opportunities and way oversold tech stocks but we need to essentially toss out the next few quarters and start to work with some new normal financial model for 2026 for valuations as this tariff situation settles into place during negotiations," Ives said.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a></li>
</ul>
Image: Shutterstock

Analyst Color

Movers

AAPL

CRWD

NVDA

PANW

Nvidia, Apple Top 'Names To Own': Cybersecurity Stocks To Outperform, Tech Analyst Dan Ives Says

Morgan Stanley analyst Mike Cyprys maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Overweight and lowers the price target from $1275 to $1124.

Morgan Stanley Maintains Overweight on BlackRock, Lowers Price Target to $1124

The Board of PureTech Health plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>, LSE: PRTC))) ("PureTech" or the "Company") notes the recent press speculation and confirms that it is in discussions with Nordic Capital Epsilon SCA, SICAV-RAIF (acting through its general partner Nordic Capital Epsilon GP SARL) ("Nordic Capital") regarding a possible cash offer to acquire the entire share capital of the Company.
A further announcement will be made as and when appropriate. There can be no certainty that any firm offer will be made for the Company, nor as to the terms on which any firm offer might be made.
In accordance with Rule 2.6(a) of the Code, Nordic Capital is required, by no later than 5.00 p.m. (London time) on 5 May 2025, being 28 days after the date of this announcement, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Takeover Panel in accordance with Rule 2.6(c) of the Code.
The person responsible for arranging release of this announcement on behalf of PureTech is Charles Sherwood, General Counsel.
This announcement is being made without the consent of Nordic Capital.

Contracts

Asset Sales

PRTC

PureTech Health Confirms Ongoing Discussions With Nordic Capital Regarding Possible Cash Offer For Entire Share Capital, With A Decision Expected By May 5, 2025

Morgan Stanley analyst Michael Cyprys maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underweight and lowers the price target from $18 to $15.

Morgan Stanley Maintains Underweight on Franklin Resources, Lowers Price Target to $15

Morgan Stanley analyst Rayna Kumar upgrades SEI Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) from Underweight to Overweight and lowers the price target from $81 to $77.

Upgrades

SEIC

Morgan Stanley Upgrades SEI Inv to Overweight, Lowers Price Target to $77

Janover Shares Resume Trade

Morgan Stanley analyst Ryan Kenny maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Underweight and lowers the price target from $70 to $42.

Morgan Stanley Maintains Underweight on Moelis, Lowers Price Target to $42

A false report claiming the Trump administration was preparing a <a href="https://www.benzinga.com/25/04/44663112/us-families-to-see-3800-annual-price-hike-says-experts-even-as-trump-indicates-tariff-windfall-of-tens-of-billions-of-dollars">90-day pause on tariffs</a> triggered a wave of volatility across U.S. equity and crypto markets on Monday.
What Happened: The confusion began when an unverified post on X suggesting a temporary tariff halt made its way to CNBC's headline feed without confirmation.
The headline was later picked up by Reuters, further amplifying the misleading report. 
The White House quickly denied the claim, telling CNBC that no such policy was under consideration and labeling the headlines as "fake news."
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44664914/bitcoin-ethereum-xrp-dogecoin-obliterate-142-billion-in-liquidations-plummet-up-to-16">Bitcoin, Ethereum, XRP, Dogecoin Obliterate $1.42 Billion In Liquidations, Plummet Up To 16%</a>
Why It Matters: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) saw a sharp swing, rising above $520 at the open before tumbling below $495 shortly after the rumor was debunked.
The index's swing represented an approximate $2 trillion loss in market value, highlighting the fragility of investor sentiment amid ongoing trade policy tensions.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), too, responded sharply to the fake headline. 
The cryptocurrency surged from $77,500 to $80,800 within minutes as hopes of a tariff pause spread. 
But once the rumor was invalidated, BTC corrected back to around $78,000, giving up most of its gains.
Nasdaq futures were also caught in the turmoil, swinging in double-digit percentage ranges. 
Analysts attributed the erratic price action to a mix of headline-driven algorithmic trading and heightened market sensitivity to geopolitical and economic policy headlines.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44657151/ripple-warns-this-country-is-falling-behind-in-the-crypto-race">Ripple Warns: This Country Is Falling Behind In The Crypto Race</a></li>
</ul>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Bitcoin Whipsaws As Trillions In Market Value Are Erased On Fake Tariff Pause Rumor

Press Releases

P3 Health Partners to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Kuehn Law Encourages Investors of P3 Health Partners Inc. to Contact Law Firm

P3 Health Partners to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Innovative Stocks to Watch: PNPN.V, NMHI, PRSO, AIFF Leading Bold Industry Transformations – More Stocks Inside!

Legal

P3 Health Partners Provides Preliminary 2025 Guidance and Announces Proposed Financing Transaction

P3 Health Partners to Participate in the TD Cowen 45th Annual Health Care Conference

P3 Health Partners to Report Fourth Quarter and Full Year 2024 Financial Results on March 27

P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results

P3 Health Partners to Participate in the 24th Annual Needham Virtual Healthcare Conference

AIFF

CSDX

GEVI

NMHI

PNPNF

PRSO

STAF

TSXV:PNPN

AirSculpt Technologies, Inc. - Common Stock

AirSculpt Technologies

American Shared Hospital Services Common Stock

American Shared Hospital

Biodesix

Basel Medical Group Ltd - ordinary shares

Basel Medical Group

Cryo-Cell International, Inc. Common Stock

Cryo-Cell International

Concord Medical Services Holdings Limited American Depositary Shares (Each represents thirty (30) Class A ordinary shares)

Concord Medical Services

DocGo

Enzo Biochem, Inc. Common Stock ($0.01 Par Value)

Enzo Biochem

Euda Health Holdings Limited - Ordinary Shares

EUDA Health Holdings

InnovAge Holding

Kindly MD

Mobile-health Network Solutions - Class A Ordinary Shares

Mobile-health Network

ModivCare

MSP Recovery, Inc. - Class A Common Stock

MSP Recovery

NewGenIvf Group Limited - Class A Ordinary Shares

NewGenIvf Group

National Research Corporation - Common Stock

National Research

Nutex Health

Ontrak

Performant Healthcare, Inc. - Common Stock

Performant Healthcare

Prenetics Global Limited - Class A Ordinary Share

Comments

P3 Health Partners

Notizie

Ultime notizie per P3 Health Partners (NASDAQ:PIII) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO